Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety Rollover Trial of Brigimadlin in Solid Tumours
NCT06619509Phase 2Active, not recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Dec 2024
- Primary completion
- Dec 2030
- Modality
- Small Molecules
- Countries
- 20
01
Overview
Phase 2, open-label, single-arm trial of brigimadlin in solid tumor, sponsored by Boehringer Ingelheim. Primary endpoint: Treatment-Emergent Adverse Events up to 9 years. Started Dec 2024; status: active, not recruiting.
02
Drugs
brigimadlin
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06619509.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06619509.